RegeneRx Biopharmaceuticals, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- J. J. Finkelstein
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 15245 Shady Grove Road Rockville MD United States of America 20850
- IPO Date
- Oct 7, 2003
- CIK
- 0000707511
- Website
- regenerx.com
- Similar Companies
- Business
- RegeneRx Biopharmaceuticals, Inc. (RGRX) is a clinical-stage biopharmaceutical company focused on the development of therapeutic peptides based on Thymosin beta 4 for tissue and organ protection, repair, and regeneration; its primary product candidates include RGN-259, a preservative-free topical eye drop in Phase 3 clinical trials for neurotrophic keratitis and dry eye disease, RGN-352, an injectable formulation targeting cardiovascular diseases, central and peripheral nervous system disorders, and other indications, and RGN-137, a topical gel for dermal wounds and scar reduction. Founded in 1982 and headquartered in Rockville, Maryland, the company operates as a virtual biopharmaceutical entity with active partnerships and licenses in the U.S., Canada, China, Pan-Asia, and the EU, including a joint venture ReGenTree LLC with HLB Therapeutics for RGN-259 development in North America where partners bear clinical costs, and strategic alliances with Lee's Pharmaceutical Group. Recent developments encompass ongoing Phase 3 trials SEER-2 and SEER-3 for RGN-259 sponsored by ReGenTree targeting complete corneal healing endpoints in neurotrophic keratitis patients with topline results anticipated in early 2024, alongside sustained licensing arrangements across Asia and Europe for its ophthalmology-focused pipeline.
RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations
RegeneRx Receives Stockholder Approval for Reverse Stock Split
RegeneRx To Extend Consent Solicitation Vote
Researchers Identify Thymosin Beta 4's Potential Role in Treatment of Acute Kidney Injury and the Reduction of Mortality in Patients with Sepsis
RegeneRx Issues Letter To Stockholders
RegeneRx JV Updates RGN-259 Regulatory Progress for Dry Eye Syndrome
RegeneRx Biopharmaceuticals, Inc. Closes $2 Million Private Placement
RegeneRx Biopharmaceuticals, Inc. Announces $2 Million Private Placement
RegeneRx Joint Venture Reports Positive Results from ARISE-3 Clinical Trial Using RGN-259 to Treat Dry Eye Syndrome
RegeneRx Reports Topline Results of ARISE-3 Dry Eye Trial
RegeneRx JV Locks Clinical Trial Database for Phase 3 Dry Eye Trial
RegeneRx Comments on ARISE-3 Clinical Trial